The Ophthalmic Pharmaceutical Market Outlook to 2014

Competitive Landscape, Pipeline Analysis, Growth Opportunities and Market Forecasts

Publication Date	September 2009
Publisher	Business Insights
Product Type	Report
Pages	158
ISBN Number	not applicable
Product Code	RBI00327

Buy this product or for assistance call +44 20 7060 7474

PDF £2,305.00$3834 | €2580

FAX Order above formats by FAX

Summary

The $13.5bn global ophthalmic pharmaceutical market demonstrated low double-digit y-o-y growth in 2008. The emergence of treatment strategies for age-macular degeneration and the subsequent therapeutic and commercial success of Lucentis has led to a substantial rise in overall size of the market while signaling the lucrative and expanding sector within ophthalmology. However, the market faces a patent cliff post 2010 due to patent expiries of class-leading products in anti-glaucoma, ocular anti-allergic and anti-infective/anti-inflammatory therapies. Subsequent generic incursion coupled with the increasing legislative priority towards healthcare reform across the globe will hurt market expansion and growth of ophthalmic franchises of leading pharmaceutical companies. Driven by good efficacy, Roche/Genentech's Lucentis and Allergan/Inspire's Restasis is expected to dominate the treatment of wet AMD and dry eye markets respectively. However Business Insights expect worldwide sales of ophthalmology treatments to remain roughly flat during 2008-14. This report provides a thorough competitive analysis of the leading brands within each indication, enabling the identification of the growth brands, major sub-therapy areas and leading players through to 2014.

Content

Executive summary
- Overview and epidemiology
- Global market analysis
- Pipeline analysis
- Competitive landscape
Chapter 1 Scope and methodology
- Scope
- Methodology
Chapter 2 Overview and epidemiology
- Summary
- Introduction
- Blindness facts
- Cataracts
- Background
- Treatment and management
- Forecast epidemiology
- Glaucoma
- Background
- Treatment and management
- Forecast epidemiology
- Retinal disorders
- Age-related macular degeneration
- Treatment and management
- Forecast epidemiology
- Diabetic retinopathy and diabetic macular edema
- Treatment and management
- Epidemiology
- Dry eye syndrome or (keratoconjunctivitis sicca)
- Background
- Treatment and management
- Forecast epidemiology
Chapter 3 Global market analysis
- Summary
- Introduction
- Historical growth trends
- Regional dynamics
- Leading ophthalmic brands
- Market analysis by drug class
- Forecast market performance drug class wise
- Key issues
- Patent cliff looms in the ophthalmic market
- Key events
- Novartis' acquisition of Alcon
- Anti-glaucoma preparations
- Leading brands
- Brand analysis
- Leading players
- Ocular anti-neovascularization preparations
- Leading brands
- Brand analysis
- Leading players
- Artificial tears
- Leading brands
- Brand analysis
- Leading players
- Ocular anti-allergics, decongestants and antiseptics
- Drug class analysis
- Leading brands
- Brand analysis
- Leading players
- Ophthalmic anti-infectives and anti-inflammatory preparations
- Drug class analysis
- Leading anti-infective brands
- Key brand analysis
- Leading anti-inflammatory brands
- Key brand analysis
- Leading anti-infectives/anti-inflammatory combination brands
- Key brand analysis
- Leading players
- Miscellaneous ophthalmic preparations
- Leading brands
Chapter 4 Pipeline analysis
- Summary
- Introduction
- Key trends, issues and events
- Protracted regulatory pathway presents entry barriers to the highgrowth DES segment
- Drug implant techniques: economic alternative to laser therapy in DME
- AMD treatment that uses VEGF-targeted siRNA strategies is in troubled waters
- Recently launched products
- Besivance
- Ozurdex
- Products in Phase III
- Bepreve
- Prolacria
- VEGF Trap-Eye
- Luveniq
- Products in Phase II
- iDestrin
- Ecabet
- Androgen Tears
- Pipeline forecasts
Chapter 5 Competitive landscape
- Summary
- Introduction
- Market concentration/fragmentation analysis
- Sales performance of leading players
- Positioning of major players in 2008 by segment
- Forecast sales performance of leading players
- Alcon
- Overview
- Dependency on ophthalmic business
- Drug class focus
- Marketed portfolio
- Pipeline portfolio
- Competitive analysis
- Allergan
- Overview
- Dependency on ophthalmic business
- Drug class focus
- Marketed portfolio
- Pipeline portfolio
- Competitive analysis
- Pfizer
- Overview
- Dependency on ophthalmic business
- Drug class focus
- Marketed portfolio
- Pipeline portfolio
- Competitive analysis
- Novartis
- Overview
- Dependency on ophthalmic business
- Drug class focus
- Marketed portfolio
- Pipeline portfolio
- Competitive analysis
- Merck & Co
- Overview
- Dependency on ophthalmic business
- Drug class focus
- Marketed portfolio
- Competitive analysis
- Santen Seiyaku
- Overview
- Dependency on ophthalmic business
- Drug class focus
- Marketed portfolio
- Pipeline portfolio
- Competitive analysis
- Bausch & Lomb
- Overview
- Dependency on ophthalmic business
- Drug class focus
- Marketed portfolio
- Pipeline portfolio
- Competitive analysis
Chapter 6 Appendix
- Definitions
- Phacoemulsification (Phaco)
- Extracapsular cataract extraction (ECCE)
- Intracapsular cataract extraction (ICCE)
- 20/40 vision
- Glossary
- Index
List of Figures
- Figure 2.1: Leading causes of blindness worldwide (%)
- Figure 2.2: Stages of progression of diabetic retinopathy
- Figure 3.3: Historical growth trend of the ophthalmic market, 2004??